USA Archives

More News! 10 Oct 2022

RadioMedix announces a $40 million series A financing for targeted alpha therapy platform

A company committed to advancing treatments for rare and aggressive cancers has received a series A funding of $40 million. Clinical stage biotech, RadioMedix, Inc. announced the agreement with an entity related to Portland Investment Counsel Inc. (Portland), on Friday (October 7). RadioMedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline […]

October 10, 2022 - 3 minutesmins - By Liza Laws

News and Trends 7 Oct 2022

AI model study may lead to identifying skin cancer from blood test

Researchers have developed an artificial intelligence (AI) model that predicts which skin cancer patients will benefit from a treatment that activates the immune defense system. The scientists are from the University of Helsinki, HUS Comprehensive Cancer Center, Aalto University and Stanford University. In practice, the AI model makes it possible to diagnose skin cancer with […]

October 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 7 Oct 2022

Beyond Biotech podcast 17: BIO-Europe, National Hemophilia Foundation

This week, we have three interviews. Our guests are: Pam Putz, managing director of EBD Group EU; André Hofmann, CEO of biosaxony; and Kevin Mills, chief scientific officer at the National Hemophilia Foundation and Teri Willey, managing director of the National Hemophilia Foundation’s Pathway to Cures. We also have our weekly chat with global commercial […]

October 7, 2022

News and Trends 6 Oct 2022

Catawba College and Eremid open genomics lab to offer undergrad training

Catawba College and Eremid Genomic Services, LLC, a genomics contract research provider, are opening the Bill and Shari Graham Genomics Laboratory specializing in genomic sequencing at Eremid’s facilities on the North Carolina Research Campus (NCRC) in Kannapolis, North Carolina. “The Graham Genomics Lab is an example of the exceptional liberal arts education offered at Catawba […]

October 6, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

FDA fast tracks Immutep non-small cell lung cancer candidate

Immutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the treatment of first line non-small cell lung cancer (NSCLC). Efti is the company’s first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

New biotech company aims to bridge gap between stem cell research and athletic injuries

Andrews Medicine of Pensacola, Florida, and Celltex Therapeutics Corporation of Houston, Texas, are to form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries. The jointly owned company will operate under the name of Andrews Celltex Biologics. The new company will undertake the operation of […]

October 5, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 5 Oct 2022

OncoSec slashing staff numbers to prioritize pipeline

OncoSec Medical Incorporated is restructuring to prioritize development of its lead clinical candidate TAVO (TAVO-EP). TAVO is a plasmid encoding interleukin 12 (IL-12) delivered by intratumoral electroporation. Oncosec is reducing its staff by approximately 45% and prioritizing clinical pipeline activities to reduce operating expenses. The company and remaining employees will focus clinical activities in melanoma […]

October 5, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Aeglea BioTherapeutics updates homocystinuria program

Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria is under way. Patients in this cohort are receiving 1.35 mg/kg of pegtarviliase once weekly administered via subcutaneous injection; patients in cohorts 1 and 2 received doses of 0.15 mg/kg and 0.45 […]

October 4, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Ginkgo Bioworks acquires Altar and Circularis

Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Altar acquisition A fleet of Altar’s automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo’s Foundry to serve customers across food and […]

October 4, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review. The study, “Improving the Efficiency of […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 4 Oct 2022

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims around the […]

October 4, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

RadioMedix announces a $40 million series A financing for targeted alpha therapy platform

AI model study may lead to identifying skin cancer from blood test

Beyond Biotech podcast 17: BIO-Europe, National Hemophilia Foundation

Catawba College and Eremid open genomics lab to offer undergrad training

FDA fast tracks Immutep non-small cell lung cancer candidate

New biotech company aims to bridge gap between stem cell research and athletic injuries

OncoSec slashing staff numbers to prioritize pipeline

Aeglea BioTherapeutics updates homocystinuria program

Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria

Ginkgo Bioworks acquires Altar and Circularis

FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium

Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!